Tiziani Whitmyre Inc. is a marketing agency specializing in revenue generation and brand development for B2B and life sciences companies - with specific capabilities in Life Science and Therapeutics.

1. FromBrand toDemand

2. TWhelpslifescienceandtechnologycompaniesmarket and
communicatecomplexproductsand servicesto build brand value,
driverevenuegeneration,orincreaseaudienceengagement.
TWprovidescriticalWebtechnologyto biotherapeutic and life
sciencecompaniesandprovidesindustry-leading responsetimes
andtechnology-focusedconsultingthat otherscan’t provide.
Howwehelp

3. Advanced Instruments
Advion
Accelrys-Velquest
Ametek-Spectro
Aushon Biosystems
Danaher-Pall
Immunetics
LabCorp-Protedyne
Medica
Quidel
Raindance Technologies
Terracon
Thrive Bioscience
Lifescience&diagnosticsclients

4. Therapeutics&pharmaclients
AvroBio
Bicycle Therapeutics
Casebia Therapeutics
Casma Therapeutics
Cedilla Therapeutics
Compass Therapeutics
Encoded Therapeutics
Faze Medicines
Intellia Therapeutics
Mirati Therapeutics
Merrimack
Pathmaker Neurosystems
Spark Therapeutics
Stoke Therapeutics
Symbiotix Biotherapies
Tango Therapeutics
20 websitescurrently maintained
for Boston agency partners
+ 25 websitesbuilt since 2016
for Boston agency partners
+

5. Targetaudiences
• Investors
• Potential employees (recruitment)
• Healthcare / physician communities
• Patient community
Biotherapeutics

6. Key website needs
• Drug development pipeline (site centerpiece)
- Informative
- Rapid updates
• Investor portal integration
• Recruitment portal help and integration
• Website design and visitor experience expertise
Biotherapeutics

7. Website trends
• Designsimplicityandelegance
Moving to improved usability and visitor experience
• Deeperbrandessenceandcolordifferentiation
Executed across all customer touchpoints
• Strongmedicalillustrations
Applying unique imagery that avoids stock photography sameness
• Searchalgorithmalignment
Ensuring site architecture and content enhance keyword search
- i.e. fast page loading, keyword-rich content
• Sitemaintenanceandsecurity
Functionality that simplifies updating and boosts cyber protection
Biotherapeutics

8. Design & development strategies
• Informative and updatable drug pipeline
• Extensible visual differentiation with greater memorability
• Friendlier visitor experience
• Multiple platform usability (desktop, tablet, mobile)
• Improved search effectiveness
• Enhanced 3rd-party portal integration
• Ease of maintenance
• Robust security
Biotherapeutics

9. Responsive
Web Design
Private Equity Partner
nextechinvest.com

10. Responsive
Web Design
encoded.com

11. Brand Color Updates
PMS 2945C
C100 M73 Y20 K6
R0 G82 B137
HEX #005289
PMS 2925C
C77 M25 Y0 K0
R0 G153 B214
HEX #0099D6
PMS 282C
C100 M87 Y42 K52
R9 G31 B64
HEX #091F40
PMS 7543C
C44 M29 Y25 K0
R149 G163 B174
HEX #95A3AE
PRIMARY COLORS
PMS 7456C
C71 M61 Y0 K0
R92 G107 B178
HEX #5C6BB2
PMS 7465C
C71 M61 Y0 K0
R85 G195 B181
HEX #55C3B5
PMS 7487C
C47 M0 Y80 K0
R145 G202 B101
HEX #91CA65
PMS 379C
C14 M0 Y73 K0
R220 G232 B85
HEX #DCE855
SECONDARY COLORS
Core Values
Posters

12. Interactive Pipeline
Responsive
Web Design
intelliatx.com

13. Environmental Graphics

14. Careers Page
Recruiting
Brochure
Core Values Interface
Talent Aquisition
intelliatx.com

15. Responsive
Web Design
mirati.com

16. Interactive Pipeline
tangotx.com

17. Interactive Pipeline Launch
Investor Portal Launch
Recruiting Integration
compasstherapeutics.com

18. Digital collateral:
Executive bios
Fact sheets
Luxterna timeline
2001
Proof of concept
shown in dogs published in
Nature Genetics
May 2008
Clinical data published
in the New England Journal of Medicine
April 2012
Orphan drug designation
received from the European Medicines Agency
(EMA) for Leber congenitial amaurosis (LCA)
March 2013
Spark Therapeutics
founded
March 2015
Orphan drug designation
received from the U.S. FDA for
retinitis pigmentosa (RP) 2
October 2007
First person dosed
in the U.S. in Children's Hospital of Philadelphia
(CHOP)-sponsored Phase 1 clinical trial
June 2008
Orphan drug designation
received from the U.S. Food and Drug Administration
(FDA) for Leber congenital amaurosis (LCA) 2
November 2012
Pivotal Phase 3
clinical trial initiated
November 2014
Breakthrough therapy designation
received from the U.S. FDA
July 2015
Orphan drug designation
received from the EMA for RP
The development of Spark Therapeutics’
investigational LUXTURNA™
(voretigene neparvovec)
Striving to challenge the inevitability of genetic
disease by discovering, developing and delivering
treatments in ways unimaginable – until now.
Built and supported the
site since 2016
Critical support through
aquisition by Roche
sparktx.com

19. Client since 2015
26 WordPress properties
Employee portal
5 languages
7 countries
Hosting in mainland China
Support of multiple business units
astronovaproductid.com

20. Naming and Identity
Brand Development
Corporate Style Guide
Website
adaptas.com

21. Why TW?
• Specialize on life science clients
• Deep experience with therapeutics firms
• Knowledge and understanding of audiences and needs
• Broad portfolio of in-house skills and resources
• Proven, comprehensive solutions that generate results

22. Addendum

23. Spark Therapeutics, Inc.
3737 Market Street
Philadelphia, PA 19104
Phone: 1-855-SPARKTX / +1 215-220-9300
© 2017 Spark Therapeutics, Inc.
sparktx.com/linkedin
communications@sparktx.com
sparktx.com
October 2016
Two-year durability data
from Phase 3 study responses presented at
the American Academy of Ophthalmology
2016 Annual Meeting
Announcement of successful completion of
the first randomized,
controlled Phase 3 trial
of a gene therapy for a genetic disease
January 2017
Amended FDA orphan drug
designation announced for “the treatment of inherited
retinal dystrophy due to biallelic RPE65 mutations”
July 2016
Safety and durability data
in contralateral eye from a Phase 1 study
published in The Lancet
January 2017
Four-year efficacy
data shown from Phase 1
follow-on study
July 2017
FDA accepts
Biologics License
Application (BLA)
Webdesign
WordPressCMSintegration
Emailcommunications
SEO
Lead/trafficgeneration
API/cloudintegrations
Marketingautomation
CRMintegration
WebServices

24. Web
Services Web design
• Mobile first
• Information storytelling
• Data driven

25. Web
Services Wordpress Integration
• Completely custom
• Security first approach
• Minimalist plug-in approach
• Uptime monitoring
• Content delivery network integration
• Translation integration and upkeep
• World-class hosting

26. Web
Services Wordpress Security
• Enterprise-class and proactive
• Monthly executive security reviews
• Local/network brute force protection
• Strong password enforcement
• Password reset enforcement
• 404 detection
• Automatic bad user lockouts
• File change detection
• Hidden login/admin
• Daily backups
• Away mode
• Email notifications
• Malware scanning
• Bi-monthly plug-in maintenance
• Activity logging
• Inactive user monitoring

27. Web
Services Email Marketing
• Mobile first
• Deliverability testing
• Designing for conversion
• Clear of purpose

28. Web
Services
SEO
• Keyword research
• Keyword selection consulting
• Keyword rank benchmarking
• Content optimization
• Content development
• Technical assessments
• Re-indexing management
• Iterative implementation and reporting

29. Web
Services Traffic generation
• Dedicated media director
• Established relationships with publishers
• Custom engagements
• Content focused
• Placements, sponsorships, networks, remarketing

30. Web
Services
• Custom API integrations
• Cost-effective 3rd-party bridges (Zapier/Piesync)
• Job boards
• CRM
• Marketing automation
• Custom analytics
• Heat map systems
Integration
Web
Services

31. Web
Services
• Customized, triggered communications
• Keep track of key stakeholder’s browsing activity
• Track businesses/organizations visiting your site
• Track outbound communications
• Create your own referral codes
Marketing Automation

32. Web
Services
• Dedicated email address for maintenance requests
• Automatic ticket generation — typically assigned same day
• Minor items .5 – 1.5 turnaround
• Custom quotes generated upon request
• Portal view to review past requests
• Team access
Support Portal

33. 2 Commercial St.
Sharon, MA 02067
tizinc.com
Contact JasonDodd or ChrisSullivan at 781-793-9380to discuss your next project.